1. Home
  2. BBNX vs STTK Comparison

BBNX vs STTK Comparison

Compare BBNX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$14.61

Market Cap

493.1M

Sector

Health Care

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$4.19

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBNX
STTK
Founded
2015
2016
Country
United States
United States
Employees
423
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.1M
538.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BBNX
STTK
Price
$14.61
$4.19
Analyst Decision
Strong Buy
Buy
Analyst Count
10
7
Target Price
$23.80
$10.00
AVG Volume (30 Days)
780.1K
860.8K
Earning Date
04-21-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.02
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
$34.90
N/A
Revenue Next Year
$34.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.80
$0.71
52 Week High
$32.71
$8.33

Technical Indicators

Market Signals
Indicator
BBNX
STTK
Relative Strength Index (RSI) 71.48 28.36
Support Level $9.34 $3.67
Resistance Level $15.53 $4.23
Average True Range (ATR) 0.96 0.51
MACD 0.27 -0.15
Stochastic Oscillator 91.73 27.29

Price Performance

Historical Comparison
BBNX
STTK

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: